Armistice Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Armistice Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-130,000	Closed	-$59.6M	–	441
2025 Q3	$59.6M	Sell	130,000 -40,000	-24%	-$14.9M	0.88%	15
2025 Q2	$51.4M	Sell	170,000 -130,000	-43%	-$38.7M	0.89%	12
2025 Q1	$99.4M	Buy	+300,000	New	+$98.6M	1.49%	9
2024 Q1	–	Sell	-280,000	Closed	-$64.8M	–	383
2023 Q4	$64.8M	Buy	280,000 +120,000	+75%	+$21M	0.88%	20
2023 Q3	$23.4M	Buy	+160,000	New	+$30.1M	0.36%	51
2023 Q2	–	Sell	-125,000	Closed	-$30.3M	–	255
2023 Q1	$30.3M	Buy	+125,000	New	+$34.1M	0.44%	48

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital's MDGL Position: Q1 2026 in Review

Armistice Capital reduced its Madrigal Pharmaceuticals (MDGL) stake by 0.42% in Q1 2026, selling an estimated $536K and leaving 264,583 shares worth $139M. The position accounts for 2.46% of the portfolio, ranked #5.

Armistice Capital first reported a position in MDGL in Q1 2015 and has held it in 40 quarters since. The position peaked at $155M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Armistice Capital held 264,583 shares of Madrigal Pharmaceuticals worth $139M as of Q1 2026.
Armistice Capital sold 1,122 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $536K.
Madrigal Pharmaceuticals made up 2.46% of Armistice Capital's portfolio in Q1 2026, its #5 holding.
Armistice Capital first reported a position in Madrigal Pharmaceuticals in Q1 2015 and has held it in 40 quarters since.
Armistice Capital's Madrigal Pharmaceuticals position peaked at $155M in Q4 2025.
378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.